The Feasibility and Efficicacy of Cervical 2 Nerve Root Coblation Combined with Myofascial Release in the Treatment of Cervicogenic Headache

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049956

Enrollment

Unknown

Registered

2021-08-15

Start date

2021-08-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervicogenic Headache

Interventions

group 1:Cervical 2 nerve root hypothermic plasma radiofrequency combined with myofascial release

group 2:Cervical 2 Nerve Root Cryogenic Plasma Radiofrequency

Eligibility

Sex/Gender

All

Age

32 Years to 73 Years

Inclusion criteria

Inclusion criteria: 1.General conditions: age >= 18 years old, BMI between 18-25, no major diseases such as cardiopulmonary disease, ASA grade I ~ III; 2.The course of disease >= 3 months, conforming to the international classification of headache disorders (3rd Edition) According to the diagnostic criteria of edition, ichd-3), in strict accordance with the expert guide of cervical headache of pain credit association of Chinese Medical Association, cervical headache is strictly distinguished from tension headache and migraine, and neurosurgeon's help is requested if necessary; 3.CT or MRI confirmed cervical disc degeneration, disc herniation, and no obvious stenosis of spinal canal and lateral recess; 4.The subjects had moderate or severe pain in most of the time, and the VAS score was >= 4; 5.Conservative treatment such as physical therapy and oral drugs has poor effect.

Exclusion criteria

Exclusion criteria: 1. Cervical spine surgery or cervical spine deformity; 2. Severe cervical disc herniation, intervertebral disc prolapse or free, spondylolisthesis, spinal instability; 3. There has been a sharp decline in limb muscle strength recently; 4. CT/MRI confirmed definite spinal canal space-occupying changes or intracranial space-occupying changes; 5. Combined with diseases that seriously affect the patient's pain perception; 6. Local infection at the puncture site or combined with systemic infection; 7. Combined with blood disease or coagulation dysfunction; 8. Combining mental and nervous system diseases cannot cooperate with the operator; 9. Combined with severe cardiopulmonary disease or liver and kidney dysfunction (ASA grade > grade III).

Design outcomes

Primary

Measure	Time frame
Therapeutic efficiency;	—

Secondary

Measure	Time frame
visual analogue pain scale;Quality of life score (QOL);	—

Countries

China

Contacts

Public ContactWu Baishan

Xuanwu Hospital of Capital Medical University

937055079@qq.com+86 13910150148

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026